Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer — NEJM
......"We evaluated the efficacy of olaparib monotherapy as maintenance
treatment in patients with platinum-sensitive, relapsed, high-grade
serous ovarian cancer who had had a response to their most recent
platinum-based chemotherapy......"
In conclusion, the results from this randomized, phase 2 study show that
maintenance treatment with olaparib was associated with a significant
improvement in progression-free survival among patients with
platinum-sensitive, relapsed, high-grade serous ovarian cancer. However,
at the interim analysis, this did not translate into an overall
survival benefit. As of this writing, 21% of the patients were still
receiving olaparib (and 3% were still receiving placebo), which
indicates that the disease is controlled for a prolonged period in some
patients.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.